Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Monday that results from its Phase III trial ESLIM-01 of sovleplenib (HMPL-523) for primary immune thrombocytopenia (ITP) have been published in The Lancet Haematology. Presented at the European Hematology Association 2024 Hybrid Congress on 14 June 2024, the study demonstrated a 48.4% durable response rate with sovleplenib compared to 0% with placebo.
Sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), showed consistent clinical benefits regardless of prior therapies or TPO/TPO-RA exposure. The trial involved 188 adult patients with primary ITP, showcasing a significant improvement in durable response and quality of life, with a median response time of eight days compared to 30 days for placebo.
The study's primary endpoint was met with 48.4% of patients achieving durable responses with sovleplenib, compared to none with placebo (p
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD